“age-related-macular-degeneration-amd” Archives

in
Entry Author Date Location
Bio Roundup: Clinical Shirkers, AMD Worriers, ASH Fallers & More 11/04/16 National
On Front Lines Of Price Dispute, Eye Doctors Wary of New Drug Data 11/01/16 National
Cellular Dynamics, National Eye Institute Announce Another Tie-up 06/22/16 Wisconsin
Kala Pharma Nabs $68M, Crossover Backers for Eye Drug Push 04/13/16 Boston
Seeking A Fresh Start in Gene Therapy, Avalanche Merges With Annapurna 02/01/16 San Francisco
Ex-Blueprint Med CEO Resurfaces With $7.5M to Fight Genetic Blindness 11/09/15 Boston
East Coast Biotech Roundup: PrecisionFDA, Avitide, Foresight & More 08/07/15 Boston
ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program 07/06/15 Detroit Ann Arbor
West Coast Biotech Roundup: Tracon, Mirati, Third Rock, & Dendreon 02/06/15 San Diego
East Coast Biotech Roundup: Maraganore, Flex, NPS, Retrophin, & More 09/15/14 Boston
RNA Therapeutics Are Here to Stay 06/05/14 San Diego
Ophthotech, Novartis Team up on $1B Deal for Eye Drug 05/19/14 New York
East Coast Biotech Roundup: Mergers, Rhythm, Regeneron, & More 05/09/14 Boston
East Coast Biotech Roundup: Sarepta, Alkermes, Boston Biotech, & More 04/25/14 Boston
Kala Pharma Grabs $22.5M More For Eye Drugs 04/23/14 Boston
East Coast Biotech Roundup: JP Morgan Edition 01/17/14 Boston
Stem Cells, Inc. Expanding Trial in Age-Related Eye Affliction 12/18/13 San Francisco
Lpath Looks to Raise $10 Million Through Secondary Offering 12/08/11 San Diego
Alexion Pharma Gobbles Up Taligen in $111M Buyout 01/31/11 Boston
ReVision Planning Late-Stage Trial Next Year for Macular Degeneration Drug 10/18/10 San Diego
Page 1 of 1